<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466985</url>
  </required_header>
  <id_info>
    <org_study_id>1439-005</org_study_id>
    <secondary_id>2011-003508-19</secondary_id>
    <nct_id>NCT01466985</nct_id>
  </id_info>
  <brief_title>A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral
      activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve,
      HIV-1-infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HIV-RNA viral load</measure>
    <time_frame>Baseline and Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed Concentration at 24 hours post-dose (C24 hr) following administration of doravirine</measure>
    <time_frame>24 hours after dosing on Days 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve from Hour 0 to Hour 24 (AUC0-24hr) following administration of doravirine</measure>
    <time_frame>From Hour 0 to Hour 24 after dosing on Days 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) following administration of doravirine</measure>
    <time_frame>Days 1-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) following administration of doravirine</measure>
    <time_frame>Days 1-7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Panel A doravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B doravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel B will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C doravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A, B, C Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on each Panel will be randomized to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).</description>
    <arm_group_label>Panel A doravirine</arm_group_label>
    <arm_group_label>Panel B doravirine</arm_group_label>
    <arm_group_label>Panel C doravirine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once daily for 7 days.</description>
    <arm_group_label>Panel A, B, C Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HIV-1-infection ≥3 months prior to screening

          -  Participants with female partner(s) of child-bearing potential must agree to use a
             medically acceptable method of contraception during the study and for 90 days after
             the last dose of study drug

          -  Body Mass Index (BMI) ≤35 kg/m^2

          -  Other than HIV infection, participant's baseline health is judged to be stable

          -  No clinically significant abnormality on electrocardiogram (ECG)

          -  Participant is ART-naïve (defined as having never received any antiretroviral agent or
             ≤30 consecutive days of an investigational antiretroviral agent (excluding an
             Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI]) or ≤60 consecutive days of
             combination ART not including an NNRTI)

          -  Participant is willing to receive no other ART for the duration of the treatment phase
             of this study.

        Exclusion Criteria:

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological (outside of HIV-1 infection), renal,
             respiratory, or genitourinary abnormalities or diseases

          -  History of clinically significant neoplastic disease

          -  Participant has used any immune therapy agents or immunosuppressive therapy within 1
             month prior to treatment in this study

          -  Participant has one or more pre-existing risk factors for Torsades de Pointes (New
             York Heart Association Functional Classification II through IV heart failure, familial
             long-QT-syndrome, uncorrected hypokalemia, QTcF &gt;470 msec)

          -  Participant requires or is anticipated to require chronic daily prescription
             medications

          -  Current (active) diagnosis of acute hepatitis due to any cause

          -  History of chronic Hepatitis C unless there has been documented cure and/or patient
             with a positive serologic test for HCV has a negative HCV viral load.

          -  Positive Hepatitis B surface antigen

          -  Participant is unable to refrain from or anticipates the use of any medication,
             including prescription and non-prescription drugs or herbal remedies (such as St.
             John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives)
             prior to administration of the initial dose of study drug, throughout the study, until
             the post-study visit

          -  Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses
             of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10
             ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

          -  Participant consumes excessive amounts, defined as greater than 6 servings (1 serving
             is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day

          -  Participant is an excessive smoker (i.e., more than 10 cigarettes/day) and is
             unwilling to restrict smoking to ≤10 cigarettes per day

          -  Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks
             prior to the prestudy (screening) visit

          -  Participation in another investigational study within 4 weeks prior to the prestudy
             (screening) visit

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             has had an anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Current regular user (including use of any illicit drugs) or has a history of drug
             (including alcohol) abuse within approximately 1 year
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Schürmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, Guo Y, Liu R, Wagner F, Wagner JA, Butterton JR, Anderson MS. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876.</citation>
    <PMID>26372481</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

